FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology for the ablation of cancer and other chronic health conditions, today announced that its agreement with Medline Industries, Inc., Mundelein, IL, for the domestic distribution of the SonicOne™ Ultrasonic Wound Debridement System has expired. In a limited release test market, Misonix and Medline have been working together to determine the best distribution model for the product. Both parties now believe that the best opportunity for market success would be sales of the product by Misonix through a proprietary distribution network. Medline will continue to close pending SonicOne™ sales opportunities through March of this year.
